Here are the 10-Q quarterly reports from Quantum-Si Incorporated Warrant (QSIAW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QSIAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QSIAW filings page.
Quantum-Si Incorporated reported Q1 2026 results showing sharply lower revenue and continued investment in proteomics R&D. Total revenue was $258 thousand, down 69.4% from $842 thousand a year earlier, mainly because customers delayed instrument and consumable purchases ahead of the anticipated Proteus platform launch by the end of 2026.
Gross profit fell to $74 thousand and gross margin declined to 28.7% from 57.7% as product mix and lower volumes weighed on profitability. Research and development expenses rose 5.6% to $14.5 million, reflecting higher lab supplies, payroll and outsourced work to advance Proteus, while selling, general and administrative costs fell 18.9% to $9.6 million due to lower legal, payroll and marketing spend.
The company recorded a net loss of $21.7 million, compared with a $19.2 million net loss in Q1 2025, and used $25.6 million in operating cash. As of March 31, 2026, Quantum-Si held $190.4 million of cash, cash equivalents and marketable securities, which management believes is sufficient to fund planned operations for at least the next twelve months.